grant
Transgenic T cell Therapy for Acute Myeloid Leukemia
Organization FRED HUTCHINSON CANCER CENTERLocation SEATTLE, UNITED STATESPosted 28 Aug 1997Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY202521+ years old5 AZC5-AC5-Aza-cytidine5-AzacytidineAML - Acute Myeloid LeukemiaAZCAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAcute leukemiaAdoptive TransferAdultAdult HumanAffectAffinityAgeAllogenicAntigenic DeterminantsAntigensAutologousAzacitidineAzacytidineBackBinding DeterminantsBlood NeutrophilBlood PlateletsBlood Polymorphonuclear NeutrophilBlood Precursor CellBlood leukocyteBody TissuesBypassCD34CD34 geneCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD62LCD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCTXCYCLO-cellCarloxanCategoriesCell BodyCell Communication and SignalingCell SignalingCellsChildhood LeukemiaCiclofosfamidaCiclofosfamideCicloxalClafenClapheneClinicalClinical TrialsClone CellsConsolidation TherapyCycloblastinCycloblastineCyclophosphamCyclophosphamideCyclophosphamidumCyclophosphanCyclophosphaneCyclophosphanumCyclostinCyclostineCytogeneticsCytophosphanCytophosphaneCytoxanDataDetectable Residual DiseaseDevelopmentDiseaseDisease remissionDisorderDorsumEndoxanEndoxanaEnduxanEngineeringEpitopesEuropeanFailureFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFosfaseronFutureGVLGene ExpressionGenesGenitourinaryGenitourinary systemGenomicsGenoxalGenuxalGuidelinesHLHRCHPCA1HSC transplantationHematopoieticHematopoietic Progenitor CellsHematopoietic Stem Cell TransplantHematopoietic Stem Cell TransplantationHematopoietic stem cellsImmune responseImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodIn VitroInduction TherapyInfusionInfusion proceduresIntracellular Communication and SignalingLAM-1 geneLECAM1LNHRLSELLYAM-1LYAM1LYT3LaboratoriesLedoxinaLentiviral VectorLentivirus VectorLeukemic CellLeukocytesLeukocytes Reticuloendothelial SystemLigandsMHC ReceptorMajor Histocompatibility Complex ReceptorMarrow NeutrophilMarrow leukocyteMarrow plateletMeasurableMediatingMemoryMinimal Residual DiseaseMitoxanMorbidityMorbidity - disease rateMorphologyNEOADJNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeosarNephroblastomaNeutrophilic GranulocyteNeutrophilic LeukocyteNewly DiagnosedNormal CellPatientsPediatric LeukemiaPhasePhase 1/2 Clinical TrialPhase 1/2 trialPhase I/II Clinical TrialPhase I/II TrialPhenotypePhysiologicPhysiologicalPlateletsPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPreventionProbabilityProcytoxProgenitor CellsProliferatingPublishingReceptor ProteinRecommendationRecoveryRegimenRelapseRemissionRenal Wilms' TumorResearchResidual NeoplasmResidual TumorsRiskSELL geneSafetySelectin L GeneSendoxanSignal TransductionSignal Transduction SystemsSignalingSyklofosfamidT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell responseT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT memory cellT-Cell Antigen ReceptorsT-Cell ReceptorT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTQ-1ThrombocytesTissuesToxic effectToxicitiesTumor AntigensTumor-Associated AntigenUrogenitalUrogenital SystemWhite Blood CellsWhite CellWilm's TumorWilms TumorWilms' Tumor of the KidneyWorkZytoxanacute granulocytic leukemiaacute granulocytic leukemia cellacute myeloblastic leukemia cellacute myelocytic leukemia cellacute myelogenous leukemia cellacute myeloid leukemiaacute myeloid leukemia cellacute nonlymphocytic leukemia celladoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyadult leukemiaadulthoodagesanalytical methodantileukemic activitybiological signal transductionblood cell progenitorblood progenitorblood stem cellblood stem cell transplantationblood-forming stem cellcancer antigenscell transductioncellular transductionchemotherapychildren with leukemiaclinical efficacyco-morbidco-morbiditycohortcomorbidityconditioningdesigndesigningdevelopmentalengineered T cellsflow cytophotometryfludarabinegenetically engineered T-cellsgraft versus leukemiagraft vs leukemiagraft vs leukemia effectgraft vs leukemia responsegraft vs. leukemiagraft vs. leukemia effectgraft vs. leukemia responsehematopoietic cell transplantationhematopoietic cellular transplantationhematopoietic progenitorhematopoietic progenitor cell transplantationhematopoietic stem progenitor cellhemopoietichemopoietic progenitorhemopoietic stem cellhigh dimensionalityhigh riskhost responseimmune system responseimmunogenimmunoresponsein vivoinduction therapiesinfusionsladakamycinleukemialeukemia in childrenleukemia relapseleukemia treatmentleukemic therapymemory T lymphocytemortalitymouse modelmurine modelneutrophilnext generationoverexpressoverexpressionpatient tolerabilitypatient toleranceperipheral bloodpre-clinicalpre-clinical efficacypre-clinical safetypreclinicalpreclinical efficacypreclinical safetypreventpreventingreceptorrecurrent leukemiarelapse riskresidual diseaseresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingstandard of carestemstem cellstherapeutic T-cell platformthymus derived lymphocytetransduced cellstransgenic T- cellstumortumor-specific antigenwhite blood cellwhite blood corpuscle
Description preview
PROJECT SUMMARY/ABSTRACT
Acute myeloid leukemia (AML) accounts for ~80% of adult acute leukemias and ~20% of childhood leukemias.
Among patients who initially achieve a complete remission with standard induction therapy, most will ultimately
relapse and die of disease-related complications. Allogeneic hematopoietic cell transplantation (HCT) has…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click